Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Bonnard

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Antiviral Therapy|November 21, 2007
Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapyOlivia Chauvel, Karine Lacombe, Philippe Bonnard, et al.
AIDS (London, England)|October 18, 2005
Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavirJean-Baptiste Guiard-Schmid, Jean-Marie Poirier, Philippe Bonnard, et al.
The Journal of Infectious Diseases|June 6, 2008
Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver diseasePatrick Soussan, Jonathan Pol, Florianne Garreau, et al.
Plos One|December 11, 2012
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patientsFlorence Abravanel, Stéphanie Raymond, Elodie Pambrun, et al.
Journal of Hepatology|August 28, 2013
Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort studyM Patrizia Carrieri, Caroline Lions, Philippe Sogni, et al.
AIDS (London, England)|April 11, 2006
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitorsJean-Marie Poirier, Jean-Baptiste Guiard-Schmid, Jean-Luc Meynard, et al.
AIDS (London, England)|May 13, 2006
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patientsStéphanie Dominguez, Jade Ghosn, Marc-Antoine Valantin, et al.
Journal of Hepatology|April 29, 2009
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patientsJulie Bottero, Karine Lacombe, Jérôme Guéchot, et al.
Antiviral Therapy|November 3, 2010
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate useAnders Boyd, Elisabeth Lasnier, Jean Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2010
Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigenCatherine Chakvetadze, Firouzé Bani-Sadr, Catherine Le Pendeven, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Antiviral Therapy|November 21, 2007
Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapyOlivia Chauvel, Karine Lacombe, Philippe Bonnard, et al.
AIDS (London, England)|October 18, 2005
Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavirJean-Baptiste Guiard-Schmid, Jean-Marie Poirier, Philippe Bonnard, et al.
The Journal of Infectious Diseases|June 6, 2008
Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver diseasePatrick Soussan, Jonathan Pol, Florianne Garreau, et al.
Plos One|December 11, 2012
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patientsFlorence Abravanel, Stéphanie Raymond, Elodie Pambrun, et al.
Journal of Hepatology|August 28, 2013
Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort studyM Patrizia Carrieri, Caroline Lions, Philippe Sogni, et al.
AIDS (London, England)|April 11, 2006
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitorsJean-Marie Poirier, Jean-Baptiste Guiard-Schmid, Jean-Luc Meynard, et al.
AIDS (London, England)|May 13, 2006
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patientsStéphanie Dominguez, Jade Ghosn, Marc-Antoine Valantin, et al.
Journal of Hepatology|April 29, 2009
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patientsJulie Bottero, Karine Lacombe, Jérôme Guéchot, et al.
Antiviral Therapy|November 3, 2010
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate useAnders Boyd, Elisabeth Lasnier, Jean Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2010
Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigenCatherine Chakvetadze, Firouzé Bani-Sadr, Catherine Le Pendeven, et al.
Pageof 4